Biogen Stock Analysis

BIIB
 Stock
  

USD 285.37  3.73  1.29%   

The current price rise of Biogen Inc could raise concerns from investors as the firm is trading at a share price of 285.37 on 952,788 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.34. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biogen partners.
Continue to Trending Equities.
  
The Biogen stock analysis report makes it easy to digest most publicly released information about Biogen and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biogen Stock analysis module also helps to analyze the Biogen price relationship with some important fundamental indicators such as market cap and management efficiency.

Biogen Stock Analysis Notes

About 88.0% of the company shares are held by institutions such as insurance companies. The book value of Biogen was currently reported as 88.72. The company recorded earning per share (EPS) of 19.62. Biogen Inc had not issued any dividends in recent years. The entity had 3:1 split on the 18th of January 2001. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people. For more info on Biogen Inc please contact Christopher Viehbacher at 617 679 2000 or go to https://www.biogen.com.

Biogen Inc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biogen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biogen Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biogen Inc is way too risky over 90 days horizon
Biogen Inc appears to be risky and price may revert if volatility continues
Biogen Inc has a strong financial position based on the latest SEC filings
Over 88.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Atlantic Equities Adjusts Price Target on Biogen to 295 From 220, Maintains Neutral Rating - Marketscreener.com

Biogen Inc Upcoming and Recent Events

Earnings reports are used by Biogen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biogen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of February 2022
Next Financial Report28th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End2nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biogen SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biogen prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biogen investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biogen Inc specific information freely available to individual and institutional investors to make a timely investment decision.
20th of July 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
3rd of May 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
7th of March 2022
Unclassified Corporate Event
View

Biogen Thematic Classifications

In addition to having Biogen stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Drugs
Drug manufacturing and delivery

Biogen Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biogen Inc backward and forwards among themselves. Biogen's institutional investor refers to the entity that pools money to purchase Biogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zwj Investment Counsel IncCommon Shares1.4 K457 K
Zwj Investment Counsel IncCommon Shares1.3 K408 K
Zwj Investment Counsel IncCommon Shares1.6 K424 K
Zwj Investment Counsel IncCommon Shares1.7 K474 K
Zweigdimenna Associates LlcCommon Shares900246 K
Zweigdimenna Associates LlcCommon Shares900255 K
Zweigdimenna Associates LlcCommon Shares30 K9.2 M
Note, although Biogen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biogen Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 41.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Biogen Profitablity

Biogen's profitability indicators refer to fundamental financial ratios that showcase Biogen's ability to generate income relative to its revenue or operating costs. If, let's say, Biogen is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biogen's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biogen's profitability requires more research than a typical breakdown of Biogen's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.28 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.0.
Last ReportedProjected for 2022
Return on Investment 15.37  19.85 
Return on Average Assets 6.42  6.59 
Return on Average Equity 14.41  19.16 
Return on Invested Capital 0.09  0.09 
Return on Sales 0.15  0.15 

Management Efficiency

The entity has return on total asset (ROA) of 0.076 % which means that it generated profit of $0.076 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.2023 %, meaning that it created $0.2023 on every $100 dollars invested by stockholders. Biogen management efficiency ratios could be used to measure how well biogen inc manages its routine affairs as well as how well it operates its assets and liabilities. The current year Return on Investment is expected to grow to 19.85. The current year Return on Average Assets is expected to grow to 6.59. Biogen Assets Non Current are projected to increase significantly based on the last few years of reporting. The past year's Assets Non Current were at 16.02 Billion. The current year Goodwill and Intangible Assets is expected to grow to about 8.1 B, whereas Total Assets are forecasted to decline to about 20.3 B.
Last ReportedProjected for 2022
Book Value per Share 73.08  68.35 
Enterprise Value over EBIT 26.00  28.05 
Enterprise Value over EBITDA 15.16  13.54 
Price to Book Value 3.23  3.90 
Tangible Assets Book Value per Share 106.61  92.77 
Enterprise Value41.3 B54.6 B
Tangible Asset Value15.9 B15.6 B
Long Term Debt Total
6.3 B
Non Current Liabilities Total
8.6 B
Short Long Term Debt Total
7.6 B
Interest Expense
253.6 M
Total Operating Expenses
6.1 B
Beta
0.2019

Technical Drivers

As of the 10th of December, Biogen shows the Risk Adjusted Performance of 0.1958, mean deviation of 2.1, and Downside Deviation of 1.86. Biogen Inc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Biogen Inc, which can be compared to its rivals. Please confirm Biogen Inc maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to decide if Biogen Inc is priced correctly, providing market reflects its regular price of 285.37 per share. Given that Biogen has jensen alpha of 0.5777, we suggest you to validate Biogen Inc's prevailing market performance to make sure the company can sustain itself at a future point.

Biogen Inc Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Kaufman Adaptive Moving Average allows the user to define Biogen Inc range across which they want the smoothing.
.

Biogen Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biogen Outstanding Bonds

Biogen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biogen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biogen bonds can be classified according to their maturity, which is the date when Biogen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Biogen Predictive Daily Indicators

Biogen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biogen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biogen Forecast Models

Biogen time-series forecasting models is one of many Biogen's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biogen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Biogen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biogen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biogen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Biogen. By using and applying Biogen Stock analysis, traders can create a robust methodology for identifying Biogen entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 25.41  29.38 
EBITDA Margin 28.27  33.81 
Gross Margin 80.79  93.20 
Profit Margin 14.17  19.09 

Current Biogen Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biogen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biogen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
316.55Hold31Odds
Biogen Inc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biogen Inc, talking to its executives and customers, or listening to Biogen conference calls.
Biogen Analyst Advice Details

Biogen Stock Analysis Indicators

Biogen Inc stock analysis indicators help investors evaluate how Biogen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biogen shares will generate the highest return on investment. By understating and applying Biogen stock analysis, traders can identify Biogen position entry and exit signals to maximize returns.
Begin Period Cash Flow1331200000.00
Logo U R LimglogosUSBIIB.png
Common Stock Shares Outstanding149600000.00
Total Stockholder Equity10896200000.00
DescriptionBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONE
Total Cashflows From Investing Activities-563700000.00
Tax Provision52500000.00
Quarterly Earnings Growth Y O Y2.532
Property Plant And Equipment Net3791800000.00
Retained Earnings13911700000.00
Cash And Short Term Investments3802500000.00
Retained Earnings Total Equity13911700000.00
Cash2261400000.00
CodeBIIB
Accounts Payable589200000.00
Net Debt5342100000.00
50 Day M A281.5976
Total Current Liabilities4298200000.00
Currency CodeUSD
Other Operating Expenses8173700000.00
Non Current Assets Total16020800000.00
Forward Price Earnings19.084
Common Stock Total Equity100000.00
Non Currrent Assets Other1941000000.00
Continue to Trending Equities. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running Biogen Inc price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.532
Market Capitalization
41.6 B
Quarterly Revenue Growth YOY
(0.1) 
Return On Assets
0.076
Return On Equity
0.2023
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine Biogen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.